Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Legend Biotech

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Appointment of Chief Medical Officer
From Legend Biotech
Via Business Wire
Tickers LEGN
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Establishes Strategic Advisory Board
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
From Legend Biotech
Via Business Wire
Tickers LEGN
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech
Via Business Wire
Tickers LEGN
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T
From Legend Biotech
Via Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Tickers LEGN
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
From Legend Biotech
Via Business Wire
Tickers LEGN
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
From Legend Biotech
Via Business Wire
Tickers LEGN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.